Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research Highlights
Nature Reviews Endocrinology 2, 62 (1 February 2006) | doi:10.1038/ncpendmet0057
Should muraglitazar be approved by the FDA for the treatment of type 2 diabetes?
Abstract
Nissen SE et al. (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581–2586 An FDA advisory committee recently recommended approval of muraglitazar, an agonist for both peroxisome proliferative-activated receptors α and γ, as monotherapy for type 2 diabetes and as combination therapy in patients with blood glucose inadequately controlled by metformin.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
